RELATED CONTENT
Biopharmaceuticals Inc. announced the first subject has been enrolled in its NAV4694 global, pivotal Phase 3 clinical trial. The trial will assess the safety and efficacy of NAV4694, an investigational positron emission tomography (PET) imaging agent, in detecting cerebral ?-amyloid in end-of-life subjects with and without the diagnosis of dementia. The study will examine the effectiveness of NAV4694 in detecting the presence or absence of ?-amyloid deposition in the brain by directly correlating the PET image findings during life with those of the brain tissue upon autopsy after death.
July 12, 2013 
Biopharmaceuticals Inc. announced results from two separate studies that compared the performance of Lymphoseek (technetium Tc 99m tilmanocept) Injection, a novel receptor-targeted small-molecule radiopharmaceutical recently approved by the U.S. Food and Drug Administration, with that of radiolabeled sulfur colloid in breast cancer patients undergoing diagnostic evaluation in lymphatic mapping procedures. The studies were presented in oral presentations at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver, Canada.
June 14, 2013